World Journal of Nephrology and Urology, ISSN 1927-1239 print, 1927-1247 online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Nephrol Urol and Elmer Press Inc
Journal website https://wjnu.elmerpub.com

Original Article

Volume 15, Number 4, November 2026, pages 95-105


Beyond Paraquat: Acute Kidney Injury Following Non-Paraquat Poisoning

Figure

↓  Figure 1. Flowchart of total non-paraquat poisonings outcomes.
Figure 1.

Tables

↓  Table 1. Baseline Demographic and Clinical Characteristics (N = 20)
 
ParameterValuePercentage/range
aDocumented history of CKD before the poisoning episode. bMean urine output (mL) recorded before initiation of RRT; the range is given in the last column. CKD: chronic kidney disease; RRT: renal replacement therapy; SD: standard deviation.
Total patients (N)20100%
Age, mean ± SD (range), years35.6 ± 12.89–58
Sex
  Male1155.0%
  Female945.0%
Type 2 diabetes mellitus420.0%
Hypertension525.0%
Known pre-existing CKDa15.0%
Pre-RRT urine output mean (mL)b560100–1,500

 

↓  Table 2. Baseline Biochemical and Laboratory Parameters at Presentation (N = 20)
 
ParameterMean ± SDRange
aSerum creatinine measured at hospital admission, before nephrology referral. Values are mean ± standard deviation (SD). ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; RRT: renal replacement therapy; SD: standard deviation.
Hemoglobin (g/dL)9.9 ± 1.58.0–14.3
Total leucocyte count (/µL)13,922 ± 7,0914,000–24,600
Platelet count (× 103/µL)208 ± 10898–481
Admission serum creatinine (mg/dL)a2.13 ± 1.290.60–4.10
Referral/RRT-initiation creatinine (mg/dL)5.87 ± 2.081.90–11.0
Serum sodium (mEq/L)131.8 ± 7.9120–145
Serum potassium (mEq/L)3.79 ± 0.812.90–5.80
Total bilirubin (mg/dL)3.42 ± 0.690.70–4.10
ALT (U/L)167.5 ± 49.624–186
AST (U/L)175 ± 5627–210
ALP (U/L)132.7 ± 41.488–225
Serum albumin (g/dL)3.53 ± 0.821.60–5.20

 

↓  Table 3. Category-Wise Distribution of Non-Paraquat Poisoning-Associated AKI (N = 20)
 
Poisoning categoryn (%)RRT modality, n
AKI: acute kidney injury; CRRT: continuous renal replacement therapy; HD: hemodialysis; PD: peritoneal dialysis.
Rodenticide (3% yellow phosphorus)4 (20%)PD (2)
Toddy adulterated with methanol2 (10%)PD (1), PD + HD + CRRT (1)
Corrosive acid ingestion2 (10%)PD (1), PD + CRRT (1)
Lithium1 (5%)PD + HD + CRRT
Supervasmol (PPD-containing hair dye)4 (20%)PD (2), PD + CRRT (2)
Phenobarbitone overdose1 (5%)CRRT (1)
Glyphosate (herbicide)3 (15%)CRRT (1), PD (1), PD + CRRT (1)
Organophosphate compound2 (10%)PD + HD (2)
Methyl salicylate1 (5%)HD + CRRT
Total20 (100)PD (20), HD (5), CRRT (9), combined (10)

 

↓  Table 4. Patient-Level Summary (N = 20)
 
S. No.Age/sexCategoryAgent consumedRRT modality
CRRT: continuous renal replacement therapy; HD: hemodialysis; OP: organophosphate; PD: peritoneal dialysis; PPD: para-phenylenediamine.
144/MHeavy metalLithiumPD
234/MRodenticideYellow phosphorus (3%)PD
330/FMethanolToddy adulterated with methanolPD
428/FCorrosiveAcidPD
550/MMethanolToddy adulterated with methanolPD
641/MPPD poisoningSupervasmol (hair dye)HD
720/FCorrosiveAcidHD
820/FPhenobarbitone/benzodiazepinePhenobarbitoneCRRT
945/FPPD poisoningSupervasmol (hair dye)PD
1037/MRodenticideRodenticideCRRT
1128/MPhosphonate herbicideGlyphosatePD
129/MPhosphonate herbicideGlyphosateCRRT + PD
1358/FPhosphonate herbicideGlyphosateCRRT
1445/MOrganophosphateOP compoundPD
1538/MRodenticideRodenticideHD
1622/MOrganophosphateOP compoundHD
1724/FSalicylateMethyl salicylateHD
1845/FPPD poisoningSupervasmol (hair dye)PD
1949/FPPD poisoningSupervasmol (hair dye)HD + CRRT
2025/MRodenticideYellow phosphorus (3%)PD

 

↓  Table 5. In-Hospital Mortality, Overall and by RRT Modality and Poisoning Category
 
OutcomenTotal (N)%
aIn-hospital deaths among patients in each poisoning category; percentage = deaths ÷ number of patients in that category. CRRT: continuous renal replacement therapy; HD: hemodialysis; PD: peritoneal dialysis; PPD: para-phenylenediamine; RRT: renal replacement therapy.
Death (in-hospital)152075.0%
Survived to discharge52025.0%
Mortality by RRT modality
  PD alone5862.5%
  PD + CRRT55100.0%
  PD + CRRT + HD1250.0%
  PD + HD1250.0%
  CRRT alone22100.0%
  HD + CRRT11100.0%
Mortality by poisoning categorya
  Supervasmol (PPD hair dye)55100.0%
  Corrosive acid ingestion22100.0%
  Lithium11100.0%
  Phenobarbitone11100.0%
  Methyl salicylate11100.0%
  Rodenticide (yellow phosphorus)3475%
  Glyphosate (herbicide)2366.7%
  Organophosphate compound1250.0%
  Toddy adulterated with methanol020.0%

 

↓  Table 6. Renal Recovery Status Among Survivors to Discharge (n = 5)
 
Renal outcome at follow-upn/N survivors% of survivors (n = 5)
CKD: chronic kidney disease.
Stable renal function/recovery2/540.0%
Progression to CKD3/560.0%
As a proportion of total cohort (N = 20)
  Renal recovery/stable, of total cohort2/2010.0%
  Progression to CKD, of total cohort3/2015.0%
  Death, of total cohort15/2075.0%

 

↓  Table 7. Prevalence of Biochemical and Hematological Abnormalities at Presentation (N = 20)
 
Abnormality (reference threshold)Patients affected, n/N%
ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; Hb: hemoglobin; TLC: total leucocyte count.
Anemia (Hb < 11 g/dL)15/2075.0%
Leucocytosis (TLC > 11,000/µL)10/2050.0%
Thrombocytopenia (platelets < 150,000/µL)6/2030.0%
Elevated admission creatinine (> 1.2 mg/dL)13/2065.0%
Hyponatremia (Na < 135 mEq/L)14/2070.0%
Hyperkalemia (K > 5.0 mEq/L)2/2010.0%
Hypokalemia (K < 3.5 mEq/L)9/2045.0%
Hyperbilirubinemia (> 1.2 mg/dL)10/2050.0%
Elevated ALT (> 40 U/L)12/2060.0%
Elevated AST (> 40 U/L)12/2060.0%
Elevated ALP (> 120 U/L)10/2050.0%
Hypoalbuminemia (< 3.5 g/dL)8/2040.0%

 

↓  Table 8. Comparison of Survivors and Non-Survivors Among Patients Requiring RRT
 
VariableSurvivors (n = 5)Non-survivors (n = 15)P-value
Values are median (interquartile range) unless otherwise stated; qSOFA score is mean ± SD. *P < 0.05, statistically significant. ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; PD: peritoneal dialysis; qSOFA: quick Sequential Organ Failure Assessment; RRT: renal replacement therapy.
Age, years34 (30–38)41 (23–45)1.000
Male sex, n (%)4 (80%)7 (46.7%)0.319
Admission creatinine, mg/dL2.1 (1.6–3.2)1.6 (0.9–3.8)0.358
Creatinine at nephrology referral/RRT, mg/dL6.8 (5.3–7.2)5.4 (4.7–6.3)0.458
Pre-RRT urine output, mL800 (400–1,000)300 (200–750)0.01*
qSOFA score1.1 ± 0.62.1 ± 0.80.001*
Use of inotropes20%55%< 0.001*
Need for ventilator40%84%< 0.001*
Duration of PD, days5 (2–5)4 (2–6)0.789
Serum sodium, mEq/L137 (131–142)131 (125–134)0.381
Serum potassium, mEq/L3.3 (3.2–4.2)3.6 (3.25–4.05)0.693
Total bilirubin, mg/dL1.5 (1.1–2.1)1.1 (0.9–1.65)0.456
ALT, U/L68 (42–112)42 (31–81)0.456
AST, U/L75 (46–128)46 (34–88)0.456
ALP, U/L145 (118–168)118 (98–150.5)0.456
Albumin, g/dL3.8 (3.5–4.0)3.5 (3.0–4.0)0.540

 

↓  Table 9. Dialyzability of the Implicated Agents Based on Published Toxicokinetic Data
 
AgentDialyzableBasis
AKI: acute kidney injury; PPD: para-phenylenediamine.
MethanolYesSmall, water-soluble, low protein binding; hemodialysis is a first-line EXTRIP-recommended treatment for methanol toxicity.
LithiumYesSmall ion, negligible protein binding; a classic dialyzable poison, with hemodialysis recommended for severe lithium toxicity.
Methyl salicylateYesLow volume of distribution and protein binding at toxic levels; hemodialysis is a standard treatment for severe salicylate poisoning.
PhenobarbitoneYesLong-acting barbiturate with relatively low protein binding and small volume of distribution; extracorporeal removal is an established EXTRIP-recommended option.
Glyphosate (herbicide)PartiallySmall, water-soluble molecule eliminated unchanged by the kidney; hemodialysis can lower plasma levels but is used mainly to support severe acidosis and AKI rather than for toxin removal per se.
Organophosphate compoundNoHighly lipid-soluble and extensively protein-bound; dialysis does not meaningfully remove the toxin and is used only to support AKI.
Rodenticide (yellow phosphorus)NoLipophilic and tissue/hepatic-bound with no established extracorporeal elimination technique; dialysis supports AKI and hepatorenal complications.
Supervasmol (PPD hair dye)NoRapidly metabolized with no established role for enhanced elimination; dialysis is used to manage AKI, hyperkalemia, and rhabdomyolysis, not to remove the toxin.
Corrosive acidNot applicableProduces local caustic injury rather than a systemic absorbed toxin; not amenable to extracorporeal removal.